Wall Street Associates decreased its position in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 86.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,100 shares of the specialty pharmaceutical company’s stock after selling 125,000 shares during the period. Wall Street Associates owned 0.09% of Adamas Pharmaceuticals worth $323,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in ADMS. BlackRock Advisors LLC raised its stake in shares of Adamas Pharmaceuticals by 10.3% in the third quarter. BlackRock Advisors LLC now owns 8,309 shares of the specialty pharmaceutical company’s stock worth $136,000 after buying an additional 774 shares during the period. American International Group Inc. raised its stake in shares of Adamas Pharmaceuticals by 57.9% in the second quarter. American International Group Inc. now owns 9,613 shares of the specialty pharmaceutical company’s stock worth $146,000 after buying an additional 3,526 shares during the period. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Adamas Pharmaceuticals during the second quarter worth about $158,000. Morgan Stanley raised its stake in shares of Adamas Pharmaceuticals by 562.3% in the third quarter. Morgan Stanley now owns 11,530 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 9,789 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Adamas Pharmaceuticals during the third quarter worth about $198,000. Hedge funds and other institutional investors own 75.83% of the company’s stock.
Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) traded up 1.724% during trading on Wednesday, hitting $16.225. 24,601 shares of the stock were exchanged. The stock’s market cap is $356.66 million. The stock’s 50 day moving average is $16.61 and its 200-day moving average is $15.51. Adamas Pharmaceuticals, Inc. has a 12-month low of $12.02 and a 12-month high of $20.74.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.17. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.26 million. Adamas Pharmaceuticals had a negative net margin of 5,267.99% and a negative return on equity of 38.31%. The business’s revenue for the quarter was down 81.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.81) EPS. Equities research analysts anticipate that Adamas Pharmaceuticals, Inc. will post ($3.02) EPS for the current year.
A number of brokerages recently issued reports on ADMS. JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Sunday, November 6th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Tuesday, November 8th. Finally, Mizuho reaffirmed a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a research note on Thursday, January 5th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $28.43.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.
Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS).